ENECADIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H28FN3O
Molecular Weight	357.4649
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC(OCCCCCN2CCCCC2)=CC(=N1)C3=CC=C(F)C=C3

InChI

InChIKey=SZSHJTJCJOWMHM-UHFFFAOYSA-N

InChI=1S/C21H28FN3O/c1-17-23-20(18-8-10-19(22)11-9-18)16-21(24-17)26-15-7-3-6-14-25-12-4-2-5-13-25/h8-11,16H,2-7,12-15H2,1H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16100702 | https://adisinsight.springer.com/drugs/800009089 | https://www.ncbi.nlm.nih.gov/pubmed/12676377 | https://www.ncbi.nlm.nih.gov/pubmed/15678048 | https://www.ncbi.nlm.nih.gov/pubmed/16187036 | https://clinicaltrials.gov/ct2/show/NCT00331721

Enecadin (NS 7 or ZK 228326) is a voltage-dependent sodium and calcium channel blocker. Enecadin is a neuroprotective agent demonstrated efficacy in animal models of ischemic injury of brain, spinal cord and retina. Enecadin was undergoing phase II development in stroke with PAION in Germany. Enecadin development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-sensitive sodium channel 7 Target ID: CHEMBL2362985 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18377333	Blocker 537
Voltage-gated calcium channel 37 Target ID: CHEMBL2363032 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18377333	Blocker 537

PubMed

Title	Date	PubMed
Cerebroprotective action of a Na+/Ca2+ channel blocker NS-7. I. Effect on the cerebral infarction and edema at the acute stage of permanent middle cerebral artery occlusion in rats.	2001 Jan 26	11164779
Electrophysiological and neurochemical evidence for voltage-dependent Ca(2+) channel blockade by a novel neuroprotective agent NS-7.	2001 Sep	11589782
Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 2nd communication: tissue distributions, placental transfer and milk secretion of radioactivity after a single intravenous 14C-NS-7 injection to rats.	2003	14650361
Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys.	2003	14558434
Neuroprotective effect of NS-7, a novel Na+ and Ca2+ channel blocker, in a focal ischemic model in the rat.	2003 Apr 18	12676377
NS-7, a novel Na+/Ca2+ channel blocker, prevents neurologic injury after spinal cord ischemia in rabbits.	2005 Feb	15678048
Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.	2005 Jun	15778734
Neuroprotective effect of the novel Na+/Ca2+ channel blocker NS-7 on rat retinal ganglion cells.	2005 Sep-Oct	16187036

Patents

Sample Use Guides

In Vitro Use Guide

In rat dorsal root ganglion neurones, NS-7 (0.3-100 microM) inhibited the whole-cell Ba(2+) currents (IBa) in a voltage-dependent manner, in which the compound more potently blocked the IBa elicited from the holding potential of -40 mV than that induced from -80 mV.

Name

Type

Language

ENECADIN

Official Name

English

Enecadin [WHO-DD]

Common Name

English

4-(4-FLUOROPHENYL)-2-METHYL-6-((5-(PIPERIDIN-1-YL)PENTYL)OXY)PYRIMIDINE

Systematic Name

English

enecadin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1509